From Nasdaq: 2025-03-21 18:15:00

Ginkgo Bioworks Holdings, Inc. (DNA) closed trading at $7.27, up 1.39%. The stock outperformed the S&P 500 and Dow, which gained 0.08%, while the Nasdaq rose by 0.52%. In the past month, the company’s shares fell 37.27%, while the Medical sector dropped 1.03% and the S&P 500 lost 7.33%.

Investors await Ginkgo Bioworks Holdings, Inc.’s earnings report with projected EPS of -$1.23, up 61.56% from last year. Revenue is estimated at $41.26 million, an 8.74% increase. For the fiscal year, estimates predict earnings of -$3.72 per share and revenue of $171.48 million, reflecting changes of +64.09% and -24.47%.

Analyst estimates for Ginkgo Bioworks Holdings, Inc. have seen recent positive revisions, indicating confidence in the company’s performance. The Zacks Rank system, with a #2 (Buy) rating for the company, has a strong track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988.

The Medical – Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 75, in the top 30% of industries. Industries in the top 50% tend to outperform the bottom half by a factor of 2 to 1. Stay updated on stock metrics with Zacks.com for the next trading sessions.

Zacks offers access to their portfolio services for $1, giving insights into picks like Surprise Trader and Technology Innovators. Thousands have benefited from this offer, closing positions with double- and triple-digit gains. Utilize Zacks Investment Research for the latest recommendations and free stock analysis reports.



Read more at Nasdaq: Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing